IP Library › Assignment 031029/0875
Patent Assignment
Reel/Frame 031029/0875

Security Agreement

Recorded: 2013-08-16 Pages: 52
Assignor
WELLSTAT THERAPEUTICS CORPORATION
Executed: 2013-08-01
Assignee
WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
88 KEARNY STREET, 4TH FLOOR, SAN FRANCISCO, CALIFORNIA, 94108
Covered Properties (96)
Treatment of Chemotherapeutic Agent and Antiviral Agent Toxicity with Acylated Pyrimidine Nucleosides
Patent: 7,776,838 →
Application: 08/460,186 →
Inhibitor of Stem Cell Proliferation and Uses Thereof
Patent: 6,610,654 →
Application: 10/128,581 →
Publication: US 2003/0104984
Compounds for the Treatment of Metabolic Disorders
Patent: 7,101,910 →
Application: 10/167,839 →
Publication: US 2003/0149107
Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Heptitis
Patent: 7,709,459 →
Application: 10/421,831 →
Publication: US 2003/0212036
Compounds for the Treatment of Metabolic Disorders
Patent: 7,329,782 →
Application: 10/481,042 →
Publication: US 2005/0256333
Compounds for the Treatment of Metabolic Disorders
Patent: 7,514,555 →
Application: 10/531,618 →
Publication: US 2006/0014784
Compounds for the Treatment of Metabolic Disorders
Patent: 7,615,575 →
Application: 10/531,630 →
Publication: US 2006/0247309
The Treatment of Metabolic Disorders
Patent: 7,645,772 →
Application: 10/532,690 →
Publication: US 2006/0035970
Compounds for the Treatment of Metabolic Disorders
Patent: 7,361,686 →
Application: 10/553,936 →
Publication: US 2007/0105955
Compounds for the Treatment of Metabolic Disorders
Patent: 7,442,796 →
Application: 10/554,586 →
Publication: US 2007/0173544
Compounds for the Treatment of Metabolic Disorders
Patent: 7,906,675 →
Application: 10/566,302 →
Publication: US 2007/0282003
Compounds for the Treatment of Metabolic Disorders
Patent: 6,924,314 →
Application: 10/684,644 →
Publication: US 2004/0077896
Compounds for the treatment of metabolic disorders
Patent: 6,858,602 →
Application: 10/684,660 →
Publication: US 2004/0236100
Compounds for the Treatment of Metabolic Disorders
Patent: 6,916,848 →
Application: 10/684,730 →
Publication: US 2004/0097585
Compounds for the Treatment of Metabolic Disorders
Patent: 7,041,659 →
Application: 10/684,735 →
Publication: US 2004/0092518
Compounds for the Treatment of Metabolic Disorders
Patent: 7,045,541 →
Application: 10/684,740 →
Publication: US 2004/0267025
Compounds for the Treatment of Metabolic Disorders
Patent: 6,946,491 →
Application: 10/685,183 →
Publication: US 2004/0092516
Compounds for the Treatment of Metabolic Disorders
Application: 10/865,088 →
Publication: US 2004/0242692
Compounds for the Treatment of Metabolic Disorders
Patent: 7,012,071 →
Application: 10/892,950 →
Publication: US 2005/0004115
Inhibitor of stem cell proliferation and uses thereof
Application: 10/897,005 →
Publication: US 2005/0043218
Compound for the treatment of metabolic disorders
Patent: 8,487,000 →
Application: 11/005,449 →
Publication: US 2005/0090555
Methods for the Treatment of Metabolic Disorders Such as Diabetes
Patent: 8,552,062 →
Application: 11/535,779 →
Publication: US 2007/0105958
Compounds for the Treatment of Metabolic Disorders
Application: 11/772,501 →
Publication: US 2007/0249696
Method for the Treatment of Metabolic Disorders
Patent: 7,851,494 →
Application: 11/772,504 →
Publication: US 2007/0265322
Method for the Treatment of Metabolic Disorders
Application: 11/772,511 →
Publication: US 2007/0249719
Method for the Treatment of Metabolic Disorders
Application: 11/772,515 →
Publication: US 2007/0244171
Method for the Treatment of Metabolic Disorders
Application: 11/772,520 →
Publication: US 2007/0244141
Method for the Treatment of Metabolic Disorders
Application: 11/772,556 →
Publication: US 2007/0265323
Method for the Treatment of Metabolic Disorders
Patent: 8,604,083 →
Application: 11/772,560 →
Publication: US 2007/0244172
Method for the Treatment of Metabolic Disorders
Patent: 7,605,181 →
Application: 11/841,489 →
Publication: US 2008/0015254
Compounds for the Treatment of Metabolic Disorders
Application: 11/841,508 →
Publication: US 2008/0015209
Compounds for the Treatment of Metabolic Disorders
Patent: 7,547,802 →
Application: 11/844,431 →
Publication: US 2008/0021109
Compounds for the Treatment of Metabolic Disorders
Patent: 7,863,475 →
Application: 11/844,432 →
Publication: US 2008/0027229
Access Control to Partitioned Blocks in Shared Memory
Application: 11/909,121 →
Publication: US 2009/0254713
Compounds for the Treatment of Metabolic Disorders
Patent: 8,178,675 →
Application: 12/092,932 →
Publication: US 2009/0203793
Compounds for the Treatment of Metabolic Disorders
Patent: 7,820,721 →
Application: 12/160,854 →
Publication: US 2008/0306165
Compounds for the Treatment of Metabolic Disorders
Patent: 7,915,429 →
Application: 12/160,857 →
Publication: US 2008/0319049
Compounds for the Treatment of Metabolic Disorders
Patent: 7,947,735 →
Application: 12/160,858 →
Publication: US 2008/0306150
Compounds for the Treatment of Metabolic Disorders
Application: 12/162,397 →
Publication: US 2009/0176885
Compositions for the Treatment of Metabolic Disorders
Patent: 7,749,990 →
Application: 12/208,877 →
Publication: US 2009/0005451
Compounds for the Treatment of Metabolic Disorders
Patent: 8,044,243 →
Application: 12/279,247 →
Publication: US 2009/0176889
Compounds for the Treatment of Metabolic Disorders
Application: 12/279,808 →
Publication: US 2010/0227901
Combination Treatment of Metabolic Disorders
Patent: 8,338,480 →
Application: 12/294,530 →
Publication: US 2010/0292277
Compounds for the Treatment of Metabolic Disorders
Patent: 7,935,689 →
Application: 12/300,239 →
Publication: US 2009/0163576
Compounds for the Treatment of Metabolic Disorders
Application: 12/304,007 →
Publication: US 2010/0234464
Combination Treatment for Metabolic Disorders
Application: 12/377,460 →
Publication: US 2010/0227809
Compounds for the Treatment of Metabolic Disorders
Patent: 7,973,052 →
Application: 12/392,675 →
Publication: US 2009/0156681
Hemoglobin Alpha Chain Peptide Fragments Useful for Inhibiting Stem Cell Proliferation
Application: 12/534,675 →
Publication: US 2010/0041147
Method for the Treatment of Metabolic Disorders
Patent: 7,932,290 →
Application: 12/550,482 →
Publication: US 2010/0087541
Compounds for the Treatment of Metabolic Disorders
Patent: 8,481,595 →
Application: 12/812,514 →
Publication: US 2010/0286267
Compounds and Method for Reducing Uric Acid
Patent: 8,829,058 →
Application: 12/920,555 →
Publication: US 2011/0014176
Tetrazole Compounds for Reducing Uric Acid
Patent: 8,410,154 →
Application: 12/989,724 →
Publication: US 2011/0206653
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Patent: 8,664,433 →
Application: 12/990,851 →
Publication: US 2011/0201838
Compounds for the Treatment of Metabolic Disorders
Application: 13/034,201 →
Publication: US 2011/0166233
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Patent: 8,703,991 →
Application: 13/127,120 →
Publication: US 2012/0004442
Compounds for the Treatment of Metabolic Disorders
Application: 13/217,977 →
Publication: US 2012/0071526
Determining the Severity of 5-Fluorouracil Overdose
Application: 13/319,563 →
Publication: US 2012/0078529
3-Substituted Compounds for Reducing Uric Acid
Patent: 8,546,448 →
Application: 13/501,338 →
Publication: US 2012/0201803
Combination Treatment for Metabolic Disorders
Application: 13/749,135 →
Publication: US 2013/0137629
Tetrazole Compounds for Reducing Uric Acid
Patent: 8,889,724 →
Application: 13/783,680 →
Publication: US 2013/0336949
Benzoic Acid Compounds for Reducing Uric Acid
Application: 13/821,402 →
Publication: US 2013/0331452
Compounds for the treatment of metabolic disorders
Application: 60/297,282 →
Compounds for the treatment of metabolic disorders
Application: 60/423,253 →
Compounds for the treatment of metabolic disorders
Application: 60/447,168 →
Compounds for the treatment of metabolic disorders
Application: 60/462,960 →
Compounds for the treatment of metabolic disorders
Application: 60/464,553 →
Compounds for the treatment of metabolic disorders
Application: 60/466,663 →
Compounds for the treatment of metabolic disorders
Application: 60/496,533 →
Compounds for the treatment of metabolic disorders
Application: 60/667,457 →
Compounds for the treatment of metabolic disorders
Application: 60/734,803 →
Combination Treatment of Metabolic Disorders
Application: 60/744,021 →
Compounds for the Treatment of Metabolic Diseases
Application: 60/747,638 →
Compounds for the treatment of metabolic disorders
Application: 60/762,066 →
Compounds for the treatment of metabolic disorders
Application: 60/762,068 →
Compounds for the treatment of metabolic disorders
Application: 60/762,091 →
Compounds for the treatment of metabolic disorders
Application: 60/764,544 →
Compounds for the treatment of metabolic disorders
Application: 60/772,687 →
Compounds for the treatment of metabolic disorders
Application: 60/777,678 →
Compounds for the Treatment of Metabolic Disorders
Application: 60/804,336 →
Combination Treatment for Metabolic Disorders
Application: 60/822,676 →
Compounds for the Treatment of Metabolic Disorders
Application: 61/021,061 →
Compounds and Method for Reducing Uric Acid
Application: 61/036,294 →
Tetrazole Compounds for Reducing Uric Acid
Application: 61/049,167 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application: 61/050,442 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application: 61/057,410 →
Tetrazole Compounds for Reducing Uric Acid
Application: 61/093,743 →
Compounds for the Treatment of Metabolic Disorders
Application: 61/096,576 →
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Application: 61/111,133 →
Determining the Severity of 5-Fluorouracil Overdose
Application: 61/177,890 →
3-Substituted Compounds for Reducing Uric Acid
Application: 61/251,098 →
Benzoic Acid Compounds for Reducing Uric Acid
Application: 61/380,882 →
3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
Application: 61/452,410 →
Stem Cell Mobilization and Tissue Regeneration
Application: 61/487,548 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application: 61/728,058 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application: 61/735,227 →
Amine Compounds Having Antiparasitic Activity
Application: 61/759,512 →
Related Assignments (10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 19, 2002
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 013219/0513 →
Assignment of Assignor's Interest Jun 18, 2003
From: TSYRLOVA, IRENA; WOLPE, STEPHEN D.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 014187/0730 →
Assignment of Assignor's Interest Dec 12, 2003
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.; BAMAT, MICHAEL K.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 015534/0374 →
Assignment of Assignor's Interest Mar 21, 2006
From: VENTURE MANAGEMENT ALLIANCE LLC
To: CDC INVESTMENTS, LLLP
Reel/Frame 017707/0189 →
Security Agreement Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
Release of Security Interest Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
Release of Certain Intellectual Property Collateral Owned by Wellstat Therapeutics Corporation Recorded at Reel 031227/Frame 0227 Jun 30, 2023
From: PDL BIOPHARMA, INC.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 064180/0456 →
Assignment of Assignor's Interest Nov 6, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065474/0475 →
Assignment of Assignor's Interest Apr 20, 2024
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 067173/0027 →
Assignment of Assignor's Interest Oct 30, 2024
From: WELLSTAT THERAPEUTICS CORPORATION
To: BTG INTERNATIONAL INC.
Reel/Frame 069079/0028 →